AzTrials
AzTrials

Cervical CancerMOOSENCT07120529

Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective Multicenter Non-inferiority Study Comparing Overall and Progression-free Survival.

An observational study of Cervical Cancer and Hysterectomy, run by Medical University of Silesia at 5 sites in Poland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this retrospective observational study with prospective follow-up is to compare the safety and treatment outcomes of radical laparoscopic hysterectomy (removal of the uterus with cervix) versus abdominal (open) hysterectomy performed after the publication of the LACC trial in women with early-stage… Read more about this study

Who is it for?
Ages 18 to 85 years, women only
Conditions the study is for
Cervical Cancer, Hysterectomy
What is being tested?
CT scan, Ultrasound scan (Transvaginal or Transabdominal) and Gynecological examination
Type of treatment
Surgery or procedure
How many people
300 participants
Where
5 sitesPoland
Study dates
15 Sep 2025to 1 Dec 2030
How long will I take part?
5 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Eligible participants will include adult, legally competent women undergoing surgery for early-stage cervical cancer (FIGO stages IB1-IIA, excluding FIGO IB3) with negative ultrastaging in sentinel node biopsy (SNB). Not using manipulator and vaginal cuff protective maneuver (either by clamping, suture from abdominal or vaginal site or with stapler) are mandatory. SNB might be a first step of the procedure followed by radical hysterectomy type B or C according to the Querleu-Morrow classification. Conization before hysterectomy is optional. Radical hysterectomy is mandatory procedure in inclusion criteria.

Who may be able to join

  • Women undergoing radical hysterectomy type B or C according to the Querleu-Morrow classification for early-stage cervical cancer (FIGO stages IB1-IIA1, excluding FIGO IB3 between November 2018 and August 2025 Not using manipulator during surgery Vaginal cuff protective maneuver during surgery Conization before surgery (optional) SNB as a first stage of treatment (optional)

Who cannot join

  • Women undergoing surgery for advanced stage cervical cancer (FIGO >IIA1) or FIGO IB3 Metastasis detected in sentinel node biopsy (confirmed in ultrastaging) ECOG>2 Not willing to participate in the study Not willing to undergo CT-scans or gynecological examinations

Trial locations and contacts

5 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Krzysztof Nowosielski, professor contact

+48 502027943

knowosielski@sum.edu.pl

5 sites in 1 country

Poland5 sites, 5 recruiting
  • Uniwersyteckie Centrum Onkologii, Uniwersytecki Szpital Kliniczny w Białymstoku

    Bialystok, 15-276

    Paweł Knapp, Professor, 85 831 80 23 ext. +48, pawel.knapp@umb.edu.pl

    Not yet recruiting
  • Department of Gynaecology, Obstetrics and Gynaecological Oncology, University Clinical Centre, Medical University of Silesia

    Katowice, 40-757

    Krzysztof Nowosielski, Professor, +48 502027943, knowosielski@sum.edu.pl

    Recruiting
  • Klinika Ginekologii, Świętokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakład Opieki Zdrowotnej

    Kielce, 25-734

    Marcin Misiek, PhD, 41 367 42 08 ext. +48, mmisiek@me.com

    Not yet recruiting
  • Oddział Ginekologii Onkologicznej z Pododdziałem Urologii, Opolskie Centrum Onkologii

    Opole, 45-061

    Ewa Milnerowicz-Nabzdyk, Professor, 77 441 6079 ext. +48, ewa.milnerowicz@wp.pl

    Recruiting
  • Department of Gynaecological Oncology,

    Wroclaw, 53-413

    Marcin Jędryka, PhD, 71 368 93 91, marcin.jedryka@umw.edu.pl

    Recruiting

Other trials in Poland

About this study

The goal of this retrospective observational study with prospective follow-up is to compare the safety and treatment outcomes of radical laparoscopic hysterectomy (removal of the uterus with cervix) versus abdominal (open) hysterectomy performed after the publication of the LACC trial in women with early-stage cervical cancer.

Eligible participants will include adult, legally competent women diagnosed with early-stage cervical cancer (FIGO stages IB1-IIA1, excluding FIGO IB3) with negative sentinel lymph node biopsy (SNB) confirmed by ultrastaging.

Read more

The main questions it aims to answer are:

Is there a difference in overall survival (OS) and progression-free survival (PFS) between laparoscopic and abdominal radical hysterectomy? Are postoperative complication rates and recurrence patterns comparable between the two surgical approaches?

Researchers will compare outcomes in patients undergoing radical laparoscopic hysterectomy versus abdominal hysterectomy to assess differences in survival, complications, and recurrence.

Participants will:

Have undergone radical hysterectomy (type B or C per Querleu-Morrow classification), preceded optionally by conization, with the use of uterine manipulators and absence of vaginal cuff protection explicitly excluded; Have had SNB as part of surgical staging; Be followed every 6 months for 5 years; Undergo clinical gynecologic examination and transvaginal and/or transabdominal ultrasound during follow-up; Undergo additional imaging (CT and/or pelvic MRI) in case of symptoms suggestive of recurrence.

All participants will follow standard post-treatment surveillance. No additional interventions beyond routine follow-up will be performed. Data on OS, PFS, complications (within 30 and 60 days postoperatively, classified by Clavien-Dindo), duration of surgery, recurrence site, and demographic characteristics will be collected.

Read the detailed description

Scientific Description This is a retrospective observational study with prospective follow-up designed to evaluate the long-term oncologic safety and perioperative outcomes of radical laparoscopic hysterectomy compared to abdominal (open) radical hysterectomy in women with early-stage cervical cancer. The study specifically addresses surgical management practices adopted after the publication of the Laparoscopic Approach to Cervical Cancer (LACC) trial, which reported inferior oncologic outcomes associated with minimally invasive surgery (MIS) for radical hysterectomy.

The primary objective of this study is to compare overall survival (OS) and progression-free survival (PFS) between the two surgical approaches. Secondary objectives include assessment of short-term surgical morbidity, recurrence patterns, and demographic and clinical factors potentially associated with adverse outcomes.

Study Population Eligible participants will be adult (≥18 years), legally competent women diagnosed with early-stage cervical cancer, defined as FIGO 2018 stages IB1 to IIA1, excluding IB3 tumors. All patients must have negative sentinel lymph node biopsy (SNB) results confirmed by ultrastaging.

To ensure homogeneity and minimize confounding associated with surgical technique, strict intraoperative criteria will be applied:

Use of a uterine manipulator is not permitted; A protective vaginal cuff closure maneuver (e.g., by suture, clamp, or stapler) must be performed to prevent tumor spillage during colpotomy; SNB may be performed as a first step, followed by radical hysterectomy classified as type B or C according to the Querleu-Morrow classification; Preoperative conization is allowed but not mandatory.

Study Design This is a retrospective cohort study with prospective follow-up. Surgical and perioperative data will be collected retrospectively from medical records. Eligible patients who underwent radical hysterectomy by either laparoscopic or abdominal approach in the post-LACC era will be identified and included.

Prospective follow-up will be conducted over a minimum period of 5 years, with evaluations scheduled at 6-month intervals.

Each follow-up visit will include:

Gynecological examination and transvaginal and/or transabdominal ultrasound; In symptomatic patients, additional imaging including contrast-enhanced CT scan of the chest, abdomen, and pelvis, and pelvic MRI as clinically indicated.

Endpoints

Primary endpoints:

Overall survival (OS): Time from radical hysterectomy to death from any cause. Progression-free survival (PFS): Time from radical hysterectomy to first documented recurrence or death.

Secondary endpoints:

Surgical complication rates within 30 and 60 days postoperatively, categorized using the Clavien-Dindo classification; Anatomic site and mode of recurrence (local, regional, or distant); Duration of surgery; Demographic and clinical variables, including age, BMI, tumor size, histologic subtype, and lymphovascular space invasion (LVSI).

Data Collection and Management Data will be extracted from patient medical records, surgical reports, pathology reports, and follow-up documentation. No study-specific interventions will be introduced beyond the standard follow-up protocol consistent with national and institutional guidelines for cervical cancer surveillance.

All clinical, surgical, and outcome data will be anonymized and stored securely. Data analysis will involve time-to-event methods (Kaplan-Meier curves, Cox proportional hazards models) and comparative statistics (e.g., chi-square, t-test, or non-parametric equivalents as appropriate).

Scientific Rationale The LACC trial demonstrated inferior disease-free and overall survival outcomes for minimally invasive radical hysterectomy compared to open surgery, which prompted a global shift in surgical practice. However, methodological concerns-including inconsistent use of uterine manipulators, absence of protective colpotomy techniques, and variability in surgeon experience-may have influenced the observed outcomes.

This study seeks to investigate whether meticulous surgical technique, standardized intraoperative precautions (such as omission of uterine manipulators and protective closure of the vaginal cuff), and proper patient selection (i.e., early-stage tumors with negative SNB) can mitigate the risks previously associated with the laparoscopic approach.

By comparing outcomes in a well-defined cohort treated after dissemination of the LACC trial results, this study aims to provide contemporary, real-world data on the oncologic safety of laparoscopic radical hysterectomy in selected early-stage cervical cancer patients.

Being tested
CT scan, Ultrasound scan (Transvaginal or Transabdominal), Gynecological examination
Keywords
cervical cancer, radical laparoscopic hysterectomy, radical abdominal hysterectomy, protective maneuver, LACC study
Medical subject headings
Uterine Cervical Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CT scanOther

    CT chest, abdominal, pelvis during follow-up

  • Ultrasound scan (Transvaginal or Transabdominal)Procedure or surgery

    Transvaginal and transabdominal ultrasound scan during follow-up

  • Gynecological examinationProcedure or surgery

    Gynecological standard examination during follow-up

Study groups in NCT07120529
Study groupRoleWhat they receive
RLHRadical laparoscopic hysterectomy
Receives: Other: CT scan; Procedure: Ultrasound scan (Transvaginal or Transabdominal); Procedure: Gynecological examination
RALRadical open hysterectomy
Receives: Other: CT scan; Procedure: Ultrasound scan (Transvaginal or Transabdominal); Procedure: Gynecological examination

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. OS

    Overall survival

    Measured: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Secondary outcomes (3)
  1. PFS

    Progression-free survival

    Measured: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  2. Complications

    Complication rate based on Clavien-Dindo Classification

    Measured: From enrollment to the 30 and 60 days postoperatively

  3. Recurrence

    site of the recurrence

    Measured: Through study completion, an average of 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2025
  2. Study start15 Sep 2025 (estimated)
  3. Primary completion1 Sep 2030 (estimated)
  4. Study completion1 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07120529
Sponsor's protocol ID
BNW/NWN/0052/KB/59/25
Acronym
MOOSE
Status last verified
Aug 2025
First submitted
6 Aug 2025
Last updated
13 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD after anonymizations will be available on request

Questions about this trial

What is this clinical trial studying?

An observational study of Cervical Cancer and Hysterectomy, run by Medical University of Silesia at 5 sites in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Krzysztof Nowosielski, professor (+48 502027943, knowosielski@sum.edu.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

OS (time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in